role
fluoroquinolon
fq
empir
therapi
communityacquir
pneumonia
cap
remain
controversi
countri
high
tuberculosi
tb
endem
owe
possibl
delay
tb
diagnosi
treatment
emerg
fq
resist
mycobacterium
tuberculosi
although
rate
macrolideresist
streptococcu
pneumonia
amoxicillinclavulan
acidresist
haemophilu
influenza
risen
alarm
level
rate
respiratori
fq
rfq
resist
amongst
isol
remain
rel
low
report
ca
cap
case
rediagnos
pulmonari
tb
asian
countri
longer
durat
day
symptom
histori
night
sweat
lack
fever
c
infect
involv
upper
lobe
presenc
cavitari
infiltr
opac
lower
lung
without
presenc
air
low
total
white
blood
cell
count
presenc
lymphopenia
predict
pulmonari
tb
amongst
patient
cap
resid
tbendem
countri
suspect
tb
imag
studi
well
aggress
microbiolog
investig
need
perform
earli
previou
exposur
fq
day
patient
tb
associ
emerg
fqresist
tuberculosi
isol
howev
rate
tuberculosi
isol
fq
resist
significantli
higher
amongst
multidrugresist
tuberculosi
isol
amongst
suscept
isol
consequ
taiwan
also
countri
tb
endem
shortcours
regimen
rfq
still
recommend
empir
therapi
cap
patient
patient
low
risk
tb
role
fluoroquinolon
fq
empir
therapi
communityacquir
pneumonia
cap
remain
controversi
countri
high
tuberculosi
tb
endem
owe
possibl
delay
tb
diagnosi
treatment
emerg
fq
resist
mycobacterium
tuberculosi
although
rate
macrolideresist
streptococcu
pneumonia
amoxicillinclavulan
acidresist
haemophilu
influenza
risen
alarm
level
rate
respiratori
fq
rfq
resist
amongst
isol
remain
rel
low
report
ca
cap
case
rediagnos
pulmonari
tb
asian
countri
longer
durat
day
symptom
histori
night
sweat
lack
fever
c
infect
involv
upper
lobe
presenc
cavitari
infiltr
opac
lower
lung
without
presenc
air
low
total
white
blood
cell
count
presenc
lymphopenia
predict
pulmonari
tb
amongst
patient
cap
resid
tbendem
countri
suspect
tb
imag
studi
well
aggress
microbiolog
investig
need
perform
earli
previou
exposur
fq
day
patient
tb
associ
emerg
fqresist
tuberculosi
isol
howev
rate
tuberculosi
isol
fq
resist
significantli
higher
amongst
multidrugresist
tuberculosi
isol
amongst
suscept
isol
consequ
taiwan
also
countri
tb
endem
shortcours
regimen
rfq
still
recommend
empir
therapi
cap
patient
patient
low
risk
tb
elsevi
bv
intern
societi
chemotherapi
right
reserv
communityacquir
pneumonia
cap
one
lead
caus
death
worldwid
mortal
rate
increas
agent
urin
cultur
posit
pneumococc
antigen
macrolideor
tetracyclinerel
agent
urin
cultur
neg
pathogen
howev
rate
penicillin
macrolid
tetracyclin
resist
amongst
pneumonia
isol
high
taiwan
antibiot
option
inpati
cap
respiratori
fluoroquinolon
rfq
levofloxacin
moxifloxacin
gemifloxacin
intens
care
unit
icu
antibiot
combin
macrolid
fluoroquinolon
fq
appropri
howev
increas
resist
key
pathogen
antibiot
pose
great
challeng
physician
taiwan
rfq
use
treatment
cap
outpati
inpati
patient
icu
rfq
shown
excel
activ
key
caus
pathogen
cap
well
atyp
pathogen
howev
use
rfq
empir
treatment
cap
might
mask
diagnosi
tuberculosi
tb
lead
delay
treatment
fq
resist
amongst
subsequ
isol
mycobacterium
tuberculosi
strain
articl
briefli
review
common
microbi
caus
cap
resist
rate
amongst
key
pathogen
proper
administr
fq
treatment
cap
incid
mortal
associ
tb
statu
multidrugresist
tuberculosi
mdrtb
taiwan
also
describ
addit
review
controversi
surround
empir
use
fq
treat
patient
cap
treatment
option
patient
delay
tb
diagnosi
emerg
fq
resist
amongst
tuberculosi
isol
lauderdal
et
al
collect
isol
patient
decemb
april
taiwan
found
common
caus
cap
amongst
adult
patient
taiwan
pneumonia
follow
atyp
pathogen
mycoplasma
pneumonia
chlamydophila
pneumonia
legionella
pneumophila
h
influenza
klebsiella
pneumonia
aetiolog
cap
undetermin
ca
cap
case
staphylococcu
aureu
caus
pathogen
cap
case
overal
mortal
rate
patient
cap
lin
et
al
found
amongst
pneumonia
strain
caus
bacteraemia
suscept
penicillin
erythromycin
tetracyclin
clindamycin
howev
suscept
cefotaxim
levofloxacin
moxifloxacin
amongst
nonbacteraem
strain
suscept
penicillin
erythromycin
tetracyclin
clindamycin
howev
rate
suscept
amongst
pneumonia
isol
cefotaxim
levofloxacin
moxifloxacin
rate
nonsuscept
pneumonia
levofloxacin
medic
centr
taiwan
peak
gradual
decreas
moxifloxacin
nonsuscept
rate
gradual
decreas
hsieh
et
al
also
show
preval
fqresist
pneumonia
isol
taiwan
low
even
though
fq
wide
use
countri
amongst
fqnonsuscept
isol
studi
serotyp
common
follow
serotyp
vaccinetyp
pneumonia
fig
show
proport
levofloxacin
resist
amongst
pneumonia
isol
major
teach
hospit
locat
differ
part
taiwan
major
pneumonia
isol
suscept
levofloxacin
suscept
rate
h
influenza
amoxicillinclavulan
acid
amc
decreas
markedli
medic
centr
taiwan
amc
administ
caution
patient
cap
addit
jean
hsueh
show
rate
extendedspectrum
esbl
produc
k
pneumonia
strain
taiwan
wang
et
al
found
resist
rate
amc
cefuroxim
cefaclor
ceftazidim
ceftriaxon
levofloxacin
amongst
k
pneumonia
isol
associ
communityacquir
respiratori
tract
infect
amongst
communityacquir
meticillinresist
aureu
camrsa
isol
medic
centr
taiwan
suscept
levofloxacin
moxifloxacin
regard
atyp
pathogen
taiwan
rate
suscept
levofloxacin
report
pneumonia
c
pneumonia
l
pneumophila
taiwan
patient
cap
previous
healthi
use
antibiot
month
prior
diseas
onset
normal
given
macrolid
doxycyclin
outpati
treatment
howev
rate
nonsuscept
penicillin
erythromycin
amongst
clinic
isol
pneumonia
increas
markedli
recent
year
therefor
caution
exercis
administ
macrolid
cap
unless
atyp
pathogen
highli
suspect
patient
comorbid
rfq
antibiot
plu
macrolid
suggest
inpati
comorbid
especi
icu
antibiot
plu
either
azithromycin
fq
suggest
atyp
pathogen
fq
effect
macrolid
length
stay
hospit
time
clinic
stabil
favour
use
fq
drago
et
al
show
combin
levofloxacin
ceftriaxon
produc
highest
rate
synergi
mainli
macrolideresist
isol
wherea
clarithromycin
combin
amc
shown
antagonist
isol
antagon
note
fq
antibiot
preval
levofloxacinresist
pneumonia
increas
markedli
period
hong
kong
especi
amongst
elderli
common
aetiolog
levofloxacin
resist
suboptim
use
fq
small
dose
mg
ofloxacin
levofloxacin
administ
two
three
time
daili
accordingli
appropri
dose
rfq
levofloxacin
mgday
moxifloxacin
mgday
gemifloxacin
mgday
recommend
incid
tb
case
per
popul
decreas
case
per
popul
sever
acut
respiratori
syndrom
sar
outbreak
fig
incid
rebound
case
per
popul
new
case
taiwan
center
diseas
control
cdc
perform
stop
tb
program
tri
reduc
incid
onehalf
tb
incid
rate
decreas
per
popul
mortal
rate
decreas
per
popul
fig
overal
number
patient
die
decreas
longterm
trend
tb
mortal
also
decreas
per
popul
per
fig
demonstr
proport
tb
amongst
patient
initi
diagnos
cap
differ
countri
rate
rang
taiwan
india
major
patient
cap
due
tb
advanc
age
year
variou
comorbid
taiwan
cdc
report
mark
differ
antimicrobi
resist
rate
patient
incid
tb
patient
recurr
tb
rate
resist
respect
isoniazid
rifampicin
ethambutol
streptomycin
firstlin
drug
http
wwwcdcgovtw
rate
resist
firstlin
drug
tend
decreas
except
rate
resist
streptomycin
remain
stabl
rate
incid
mdrtb
rate
resist
drug
class
well
incid
mdrtb
also
show
downward
trend
decad
period
fq
resist
rate
amongst
nonmdrtb
isol
taiwan
amongst
isol
patient
previou
antitb
treatment
amongst
mdrtb
isol
wang
et
al
evalu
fq
suscept
well
genet
mutat
amongst
isol
patient
expos
fq
januari
decemb
found
multipl
drug
resist
strongest
correl
fq
resist
isol
neither
previou
use
fq
durat
fq
exposur
correl
fq
suscept
amongst
fqresist
isol
gyra
mutat
gyrb
mutat
amongst
mdrtb
isol
taiwan
report
yu
et
al
resist
ofloxacin
rate
extens
drugresist
tb
xdrtb
isol
isol
accord
annual
report
taiwan
cdc
rate
fqresist
mdrtb
isol
juli
march
http
wwwcdcgovtw
total
mdrtb
isol
also
resist
capreomycin
amikacin
kanamycin
rate
xdrtb
amongst
mdrtb
isol
nearli
fqresist
tuberculosi
isol
found
amongst
mdrtb
isol
fig
common
site
fqresist
tuberculosi
isol
obtain
genitourinari
tract
pulmonari
tract
pleural
caviti
dooley
et
al
first
point
possibl
empir
treatment
fq
might
delay
diagnosi
tb
amongst
patient
receiv
empir
fq
treatment
median
time
symptom
onset
receipt
antitb
medic
day
compar
median
time
day
amongst
receiv
fq
howev
sampl
size
studi
small
patient
receiv
fq
receiv
antitb
therapi
patient
receiv
antibiot
treatment
initi
acidfast
bacillu
smear
posit
patient
tb
suspect
least
onehalf
patient
receiv
fq
antibiot
prescrib
antitb
treatment
given
directli
interestingli
patient
receiv
fq
monotherapi
experienc
improv
symptom
tb
clinic
improv
occur
averag
day
initi
therapi
studi
also
report
delay
initi
antitb
medic
longer
amongst
patient
receiv
fq
amongst
patient
receiv
fqbase
antibiot
day
vs
day
p
median
healthcar
delay
patient
receiv
antibiot
nontb
diagnosesind
prior
tb
diagnosi
day
versu
day
p
patient
initi
receiv
tb
therapi
administr
fq
result
delay
diagnosi
tb
median
day
administr
antibiot
macrolid
carbapenem
similar
effect
median
day
studi
golub
et
al
patient
initi
diagnos
pneumonia
chest
radiograph
interestingli
chest
radiograph
suggest
diagnosi
tb
howev
patient
still
subsequ
prescrib
empir
antibiot
importantli
antibiot
use
chest
radiograph
taken
first
healthcar
visit
independ
relat
longer
healthcar
delay
overal
cohort
mathur
et
al
show
ca
activ
tb
patient
given
incorrect
diagnosi
initi
present
mainli
atyp
radiograph
manifest
studi
malaysia
clearli
demonstr
durat
symptom
week
hospit
admiss
odd
ratio
p
histori
night
sweat
p
chest
radiograph
show
upper
lobe
involv
p
cavitari
infiltr
p
total
white
blood
cell
count
l
admiss
p
lymphopenia
p
significantli
associ
cultureposit
pulmonari
tb
fig
addit
lower
lung
field
tb
llftb
difficult
differenti
pneumonia
often
fig
clinic
laboratori
predictor
patient
tuberculosi
initi
diagnos
communityacquir
pneumonia
cxr
chest
radiographi
wbc
white
blood
cell
count
misdiagnos
atyp
find
chest
radiograph
taiwan
ca
pulmonari
tb
patient
llftb
multivari
analysi
conduct
lin
et
al
show
prolong
durat
symptom
day
p
lack
fever
c
p
absenc
air
bronchogram
p
signific
predictor
llftb
patient
llf
pneumonia
calcul
probabl
park
et
al
evalu
impact
shortterm
exposur
fq
ofloxacin
resist
human
immunodefici
viru
hiv
neg
patient
tb
found
rate
ofloxacinresist
tuberculosi
low
case
ofloxacin
resist
associ
mdrtb
also
found
frequenc
ofloxacinresist
tuberculosi
low
amongst
patient
expos
fq
short
period
time
find
favour
applic
fq
regimen
cap
tb
patient
shorter
diseas
durat
taiwan
patient
cap
receiv
final
diagnosi
tb
import
differenti
cap
tb
initi
present
lesion
locat
upper
lung
field
clinic
specimen
collect
rapid
nucleic
acid
amplif
could
shorten
delay
tb
diagnosi
rather
restrict
empir
treatment
fq
cap
lesion
lower
lobe
risk
factor
includ
advanc
age
prolong
durat
lesion
lack
fever
absenc
air
bronchogram
rais
suspicion
llftb
although
use
fq
taiwan
high
incid
tb
mortal
rate
associ
tb
rate
drug
resist
decreas
rate
fq
resist
pneumonia
low
rate
suscept
fq
high
amongst
h
influenza
k
pneumonia
includ
esblproduc
strain
atyp
pathogen
camrsa
taiwan
high
incid
cap
caus
atyp
pathogen
taiwan
coverag
atyp
pneumonia
must
consid
empir
treatment
cap
outpati
inpati
macrolid
use
caution
high
rate
resist
antimicrobi
class
pneumonia
fq
good
synergist
effect
antimicrobi
agent
except
macrolid
combin
might
show
antagonist
properti
empir
treatment
cap
fq
might
mask
activ
tb
delay
treatment
contribut
develop
fq
resist
fq
resist
tuberculosi
relat
fq
durat
time
exposur
exposur
fq
day
exposur
day
tb
diagnosi
shown
associ
signific
risk
develop
fq
resist
consequ
taiwan
well
countri
endem
tb
shortcours
regimen
fq
levofloxacin
moxifloxacin
gemifloxacin
still
recommend
empir
therapi
cap
patient
patient
low
risk
tb
furthermor
fq
resist
less
like
occur
amongst
tuberculosi
strain
isol
patient
shortterm
exposur
day
fq
fund
fund
sourc
compet
interest
none
declar
ethic
approv
requir
